Violation Tracker Agency Summary Page
Agency Name:
Multistate Attorneys General Case
Penalty Total since 2000:
$148,276,868,927
Number of Records:
692
Note:
The penalty total above and the parent totals below include some cases in which both a state and a federal agency were involved and issued separate announcements of the outcome. The individual penalty records below marked by an asterisk are ones for which Violation Tracker contains a separate federal entry.
| Top 10 Parent Companies | Total Penalty $ | Number of Records |
|---|---|---|
| Bank of America | $26,114,848,408 | 10 |
| UBS | $11,393,380,000 | 5 |
| Purdue Pharma | $10,179,500,000 | 3 |
| Citigroup | $8,235,591,577 | 7 |
| McKesson | $8,152,000,000 | 2 |
| AmerisourceBergen | $6,623,275,000 | 3 |
| Cardinal Health | $6,489,000,000 | 1 |
| JPMorgan Chase | $6,208,338,661 | 10 |
| Johnson & Johnson | $6,110,541,516 | 10 |
| BP | $4,910,000,000 | 2 |
Individual Penalty Records:
Click on the company or penalty amount for more information on each case. Click on the parent name to reach the summary page for that parent company.
| Company | Parent | Parent Major Industry | Primary Offense Type | Year |
Penalty Amount |
|---|---|---|---|---|---|
| UBS Securities LLC and UBS Financial Services, Inc. | UBS | financial services | investor protection violation | 2008 | $11,150,000,000 |
| Purdue Pharma | Purdue Pharma | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | $10,000,000,000 |
| Countrywide Home Loans | Bank of America | financial services | mortgage abuses | 2008 | $8,680,000,000 |
| McKesson Corporation | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2021 | $8,001,000,000 |
| Citigroup Global Markets, Inc. and Citi Smith Barney | Citigroup | financial services | investor protection violation | 2008 | $7,100,000,000 |
| AmerisourceBergen Corporation | AmerisourceBergen | wholesalers | off-label or unapproved promotion of medical products | 2021 | $6,510,000,000 |
| Cardinal Health Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2021 | $6,489,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | $5,000,000,000 |
| BP | BP | oil and gas | environmental violation | 2015 | (*) $4,900,000,000 |
| American Electric Power | American Electric Power | utilities and power generation | environmental violation | 2007 | (*) $4,675,000,000 |
| Banc of America Securities LLC | Bank of America | financial services | investor protection violation | 2008 | $4,550,000,000 |
| Morgan Stanley | Morgan Stanley | financial services | investor protection violation | 2008 | $3,535,000,000 |
| JP Morgan Chase & Co. | JPMorgan Chase | financial services | investor protection violation | 2008 | $3,525,000,000 |
| Merrill Lynch & Co. | Bank of America | financial services | investor protection violation | 2008 | $3,458,333,333 |
| Goldman Sachs Group, Inc. | Goldman Sachs | financial services | investor protection violation | 2008 | $3,355,833,333 |
| Deutsche Bank Securities, Inc. and Deutsche Bank AG | Deutsche Bank | financial services | investor protection violation | 2008 | $3,348,333,333 |
| Countrywide Financial Corporation | Bank of America | financial services | mortgage abuses | 2010 | $3,004,100,000 |
| Bank of America | Bank of America | financial services | investor protection violation | 2012 | $2,430,000,000 |
| Bank of America | Bank of America | financial services | mortgage abuses | 2012 | (*) $2,382,415,075 |
| Mallinckrodt | Mallinckrodt | pharmaceuticals | Controlled Substances Act violation | 2020 | $1,600,000,000 |
| Enron | Enron | utilities and power generation | energy market manipulation | 2005 | $1,520,000,000 |
| El Paso Corporation | Kinder Morgan | pipelines | energy market manipulation | 2003 | $1,450,000,000 |
| JPMorgan Chase | JPMorgan Chase | financial services | mortgage abuses | 2012 | (*) $1,121,188,661 |
| JPMorgan Chase | JPMorgan Chase | financial services | toxic securities abuses | 2013 | (*) $1,066,000,000 |
| Wells Fargo | Wells Fargo | financial services | mortgage abuses | 2012 | (*) $1,005,233,716 |
| Bank of America Corporation | Bank of America | financial services | mortgage abuses | 2014 | (*) $943,000,000 |
| RBC Capital Markets Corporation | Royal Bank of Canada | financial services | investor protection violation | 2008 | $859,800,000 |
| Marsh & McLennan Companies, Inc. | Marsh & McLennan | financial services | price-fixing or anti-competitive practices | 2005 | $850,000,000 |
| Standard & Poor's Financial Services LLC | S&P Global | information technology | toxic securities abuses | 2015 | (*) $687,500,000 |
| TK Holdings Inc. | Ningbo Joyson Electronic | automotive parts | consumer protection violation | 2018 | $650,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*) $612,000,000 |
| Wells Fargo Bank N.A. | Wells Fargo | financial services | banking violation | 2018 | $575,000,000 |
| McKinsey & Company | McKinsey | business services | off-label or unapproved promotion of medical products | 2021 | $573,000,000 |
| Volkswagen | Volkswagen | motor vehicles | environmental violation | 2016 | (*) $570,000,000 |
| Santander Consumer USA Inc. | Banco Santander | financial services | consumer protection violation | 2020 | $550,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*) $541,000,000 |
| Bank of America | Bank of America | financial services | investor protection violation | 2013 | $500,000,000 |
| Career Education Corp. | Perdoceo Education Corporation | miscellaneous services | consumer protection violation | 2019 | $498,700,000 |
| Household Finance Corp. | HSBC | financial services | mortgage abuses | 2002 | $484,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*) $477,792,391 |
| Mylan Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2017 | (*) $465,000,000 |
| Reliant Energy, Inc. | NRG Energy | utilities and power generation | energy market manipulation | 2005 | $460,000,000 |
| TD Ameritrade, Inc. | Charles Schwab Corp. | financial services | investor protection violation | 2009 | $456,000,000 |
| Apple Inc. | Apple Inc. | electrical and electronic equipment | price-fixing or anti-competitive practices | 2014 | $450,000,000 |
| Moody's Corporation | Moody's | information technology | toxic securities abuses | 2017 | (*) $426,500,000 |
| Williams Energy Marketing & Trading | Williams Companies | oil and gas | energy market manipulation | 2002 | $417,000,000 |
| Citigroup | Citigroup | financial services | mortgage abuses | 2012 | (*) $413,041,577 |
| Marsh and McLennan | Marsh & McLennan | financial services | investor protection violation | 2009 | $400,000,000 |
| Salomon Smith Barney Inc. | Morgan Stanley | financial services | investor protection violation | 2002 | (*) $400,000,000 |
| Reckitt Benckiser Group | Reckitt Benckiser | household and personal care products | False Claims Act and related | 2019 | $400,000,000 |
| LG Display Co., Ltd. | LG | diversified | price-fixing or anti-competitive practices | 2012 | $380,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | False Claims Act and related | 2016 | (*) $371,351,180 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | (*) $361,828,456 |
| Archer Daniels Midland Company | Archer Daniels Midland | agribusiness | environmental violation | 2003 | (*) $350,900,000 |
| Abbott Laboratories | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*) $339,148,643 |
| Pfizer, Inc. | Pfizer | pharmaceuticals | kickbacks and bribery | 2009 | (*) $331,485,170 |
| ITT Technical Institute and PEAKS | ITT Technical Institute | miscellaneous services | consumer protection violation | 2020 | $330,000,000 |
| Ameriquest Mortgage | Citigroup | financial services | consumer protection violation | 2006 | $325,000,000 |
| Invesco Funds Group | Invesco | financial services | investor protection violation | 2004 | (*) $325,000,000 |
| MCI | Verizon Communications | telecommunications | tax violations | 2005 | $315,000,000 |
| Olympus Corporation of the Americas | Olympus | electrical and electronic equipment | False Claims Act and related | 2016 | (*) $306,000,000 |
| Indivior plc | Indivior Inc. | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | $300,000,000 |
| S&M Brands, Inc. | tobacco litigation | 2021 | $300,000,000 | ||
| Schering-Plough Corporation | Merck | pharmaceuticals | kickbacks and bribery | 2004 | (*) $292,969,482 |
| Citigroup Inc. | Citigroup | financial services | toxic securities abuses | 2014 | (*) $291,750,000 |
| Merck | Merck | pharmaceuticals | False Claims Act and related | 2008 | (*) $290,000,000 |
| Prudential Equity Group | Prudential Financial | financial services | investor protection violation | 2006 | (*) $270,000,000 |
| Ranbaxy | Sun Pharmaceuticals | pharmaceuticals | drug or medical equipment safety violation | 2013 | (*) $266,729,715 |
| Serono Inc. | Merck KGaA (EMD) | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | (*) $262,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*) $257,400,000 |
| Samsung Electronics, Co., Ltd. | Samsung | diversified | price-fixing or anti-competitive practices | 2011 | $240,000,000 |
| Goldman Sachs | Goldman Sachs | financial services | toxic securities abuses | 2016 | (*) $225,000,000 |
| Janus Capital Management | Janus Henderson | financial services | investor protection violation | 2004 | $225,000,000 |
| Deutsche Bank | Deutsche Bank | financial services | interest rate benchmark manipulation | 2017 | $220,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*) $218,092,993 |
| Dish Network | DISH Network | telecommunications | privacy violation | 2020 | (*) $210,000,000 |
| Duke Energy | Duke Energy | utilities and power generation | energy market manipulation | 2004 | $207,500,000 |
| Merck Sharp & Dohme Corp. | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*) $201,975,000 |
| Credit Suisse First Boston Corp. | Credit Suisse | financial services | investor protection violation | 2002 | (*) $200,000,000 |
| Reckitt Benckiser Group | Reckitt Benckiser | household and personal care products | Controlled Substances Act violation | 2019 | (*) $200,000,000 |
| WellCare Health Plans Inc. | Centene | healthcare services | investor protection violation | 2010 | $200,000,000 |
| Aequitas Capital Management Inc. | consumer protection violation | 2017 | $192,000,000 | ||
| Aon Corporation | Aon | financial services | price-fixing or anti-competitive practices | 2005 | $190,000,000 |
| Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | (*) $190,000,000 |
| Boston Scientific Corporation | Boston Scientific Corp. | medical equipment and supplies | drug or medical equipment safety violation | 2021 | $188,600,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2008 | (*) $187,000,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | $181,000,000 |
| Equifax | Equifax | miscellaneous services | privacy violation | 2019 | $175,000,000 |
| Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | (*) $173,000,000 |
| Zurich American Insurance Company | Zurich Insurance | financial services | price-fixing or anti-competitive practices | 2006 | $171,700,000 |
| AU Optronics Corporation | AU Optronics | electrical and electronic equipment | price-fixing or anti-competitive practices | 2012 | $170,000,000 |
| Teva Pharmaceuticals Inc. | Teva Pharmaceutical Industries | pharmaceuticals | False Claims Act and related | 2010 | $169,000,000 |
| Student CU Connect CUSO, LLC | consumer protection violation | 2019 | (*) $168,000,000 | ||
| SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | pharmaceuticals | drug or medical equipment safety violation | 2010 | (*) $163,560,000 |
| Purdue Frederick Company Inc. | Purdue Pharma | pharmaceuticals | False Claims Act and related | 2007 | (*) $160,000,000 |
| Volkswagen AG | Volkswagen | motor vehicles | environmental violation | 2017 | $157,000,000 |
| Par Pharmaceuticals, Inc. | Endo International | pharmaceuticals | False Claims Act and related | 2011 | $154,000,000 |
| McKesson Corporation | McKesson | wholesalers | False Claims Act and related | 2012 | $151,000,000 |
| Brown & Williamson Tobacco | British American Tobacco | tobacco | tobacco litigation | 2003 | $150,000,000 |
| JPMorgan Chase | JPMorgan Chase | financial services | investor protection violation | 2015 | $150,000,000 |
| Uber Technologies | Uber Technologies | miscellaneous services | privacy violation | 2018 | $148,000,000 |
